Genenta Science S.p.A.

Develops cell & gene therapies using engineered stem cells to treat solid tumors.

GNTA | NDAQ

Overview

Corporate Details

ISIN(s):: US36870W1009
LEI:
Country:: United States of America
Address:: OLGETTINA, NO. 58, 20132 MILAN
Website:: https://www.genenta.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Genenta Science S.p.A. is a clinical-stage immuno-oncology company developing proprietary cell and gene therapies for the treatment of solid tumors. The company's technology is centered on engineering a patient's own hematopoietic stem cells using a lentiviral vector to combat cancer. Its lead candidate, Temferon, is designed to make tumors visible to the immune system by reprogramming the tumor microenvironment and breaking immune tolerance. Genenta has completed a Phase 1 clinical trial in Glioblastoma Multiforme and has initiated a Phase 1/2a study in metastatic Renal Cell Carcinoma. The treatments are designed as one-time monotherapies that also have the potential to be used in combination to enhance the efficacy of other therapeutics, such as immune checkpoint inhibitors.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Genenta Science S.p.A. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Genenta Science S.p.A.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for Genenta Science S.p.A. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
CERO THERAPEUTICS HOLDINGS, INC. Develops engineered T-cell immunotherapies for cancer using its proprietary CER platform.	United States of America	CERO
CervoMed Inc. Developing CNS therapeutics for neurodegenerative diseases like dementia with Lewy bodies.	United States of America	CRVO
Cessatech A/S Develops a non-invasive nasal spray for acute pain relief in children during medical procedures.	Denmark	CESSA
CG Invites Co., Ltd. Biopharma advancing precision medicine with drugs, mRNA vaccines, and digital therapeutics.	South Korea	083790
CG Oncology, Inc. Developing bladder-sparing oncolytic immunotherapies for patients with bladder cancer.	United States of America	CGON
CHA Vaccine Research Institute Develops vaccines and immunotherapies for infectious diseases and cancer using proprietary platforms.	South Korea	261780
CHEIL BIO CO., LTD. Manufactures veterinary medicines and feed additives for livestock, aquatic animals, and pets.	South Korea	052670
Chemical Works of Gedeon Richter Plc Develops and manufactures drugs for women's health, CNS, and cardiovascular diseases.	Hungary	RICHT
Chemomab Therapeutics Ltd. Develops antibody drugs neutralizing CCL24 for severe fibro-inflammatory diseases.	United States of America	CMMB
CHINA PHARMA HOLDINGS, INC. Develops, manufactures, and sells prescription, OTC, and nutritional products for human use.	United States of America	CPHI